The effect of prior COVID-19 infection on coronary microvascular dysfunction

Bilge, Önder; Çap, Murat; Kepenek, Ferat; Erdoğan, Emrah; Tatlı, İsmail; Öztürk, Cansu; Taştan, Ercan; Gündoğan, Cihan; Işık, Ferhat; Okşul, Metin; Oktay, Mesut; Akın, Halil; Burak, Cengiz; Karahan, Mehmet Zülküf; Kömek, Halil; Tanboğa, İbrahim Halil

doi:10.1080/00015385.2022.2067641

Cited by 7 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study concluded that COVID-19 patients had infection-triggered mechanisms, which ultimately resulted in the development of CMD. Although this finding has been confirmed in several studies, especially in hospitalized patients with COVID-19, the severity of CMD among COVID-19 patients appears to vary partly because of the virus variant that caused the disease [34–39]. Importantly, a very recent study in the United Kingdom identified microangiopathic thrombosis as a common cause of myocardial injury in hospitalized COVID-19 patients with troponin elevation [40].…”

Section: Coronary Microcirculationmentioning

confidence: 85%

Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19

Vuorio

Raal

Kovanen

2023

Current Opinion in Lipidology

View full text Add to dashboard Cite

Purpose of reviewPatients with heterozygous familial hypercholesterolemia (HeFH) are at increased risk for COVID-19 cardiovascular complications in the acute phase of the infection. Elevated levels of LDL-C and often lipoprotein(a) are present from birth and lead to endothelial dysfunction, which is aggravated by a direct viral attack of the endothelial cells and their exposure to the toxic levels of circulating proinflammatory and prothrombotic mediators during the hyperinflammatory reaction typical of COVID-19. Recent findingsEvidence to date shows the benefit of lipid-lowering therapy in patients with COVID-19. In HeFH patients who are at much higher cardiovascular risk, the focus should, therefore, be on the effective lowering of LDL-C levels, the root cause of the greater cardiovascular vulnerability to COVID-19 infection in these patients. The ongoing use of statins and other lipid-lowering therapies should be encouraged during the ongoing COVID pandemic to mitigate the risk of cardiovascular complications from COVID-19, particularly in HeFH patients. SummaryEpidemiologic registry data show that the incidence of myocardial infarction is increased in SARS-CoV-2infected HeFH patients. There is a need to study whether the risk for acute cardiovascular events is increased in the long-term and if there are changes in lipid metabolism after SARS-CoV infection(s) in patients with HeFH.

show abstract

Section: Coronary Microcirculationmentioning

confidence: 85%

Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19

Vuorio

Raal

Kovanen

2023

Current Opinion in Lipidology

View full text Add to dashboard Cite

show abstract

Section: Cardiac Imaging In the Diagnosis Of Early Complications Of C...mentioning

confidence: 99%

“…AF occurs more commonly with COVID compared with many other respiratory diseases. 99,131 New onset AF occurred in 5.4% of 31 000 patients hospitalized for COVID and was associated with increased in-hospital mortality and major adverse cardiac events. 100 Transesophageal echocardiography is typically used to image the left atrial appendage (LAA) before direct current cardioversion for AF.…”

Section: Af and Left Atrial Appendage Thrombusmentioning

confidence: 99%

Multimodality Cardiac Imaging in COVID

Holby

Richardson

Laws

et al. 2023

Circulation Research

View full text Add to dashboard Cite

Infection with SARS-CoV-2, the virus that causes COVID, is associated with numerous potential secondary complications. Global efforts have been dedicated to understanding the myriad potential cardiovascular sequelae which may occur during acute infection, convalescence, or recovery. Because patients often present with nonspecific symptoms and laboratory findings, cardiac imaging has emerged as an important tool for the discrimination of pulmonary and cardiovascular complications of this disease. The clinician investigating a potential COVID-related complication must account not only for the relative utility of various cardiac imaging modalities but also for the risk of infectious exposure to staff and other patients. Extraordinary clinical and scholarly efforts have brought the international medical community closer to a consensus on the appropriate indications for diagnostic cardiac imaging during this protracted pandemic. In this review, we summarize the existing literature and reference major societal guidelines to provide an overview of the indications and utility of echocardiography, nuclear imaging, cardiac computed tomography, and cardiac magnetic resonance imaging for the diagnosis of cardiovascular complications of COVID.

show abstract

“…Thrombolysis in Myocardial Infarction Frame Count (TFC) is an index that provides a quantitative evaluation of coronary microvascular dysfunction. In their single-center retrospective study concerning 210 patients including 48 with a history of COVID-19, Bilge et al showed that TFC may be elevated due to coronary microvascular dysfunction in patients with a history of COVID-19 [5]. Akt€ urk et al reported the management and clinical outcomes of 239 patients with acute coronary syndrome (ACS) before and during pandemic [6].…”

Section: Focus Issue On Diagnostic Work-up and Prognostic Assessment ...mentioning

confidence: 99%